Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients

Review (70 studies; n=17,462) found in studies with follow‐up to 3 years, TOR‐I with antimetabolite (AM) increases risk of graft loss and acute rejection compared with calcineurin inhibitor and AM. TOR‐I with CNI potentially offers alternative to AM with CNI.


Cochrane Database of Systematic Reviews